SGH to advance cancer treatment in new partnership

The collaboration will drive cord blood-derived allogeneic CAR T-cell development.

Singapore General Hospital (SGH) has entered an agreement with Charles River Laboratories International Inc. to drive the development of cord blood-derived allogeneic chimeric antigen receptor (CAR) T-cells for cancer treatment.

Under the agreement, SGH will use Charles River’s current good manufacturing practice-compliant master cell banking services for the critical starting materials for allogeneic CAR T-cells.

In addition, next-generation sequencing-based testing services will be used for cell line characterisation as part of SGH’s upcoming Phase I clinical trials.

Follow the link s for more news on

Singapore General Hospital

hospitals

oncology market

partnership

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia